attana - sensor technologies

Mapping the immunogenicity of therapeutic protein products

It is of great importance to understand and verify desired and unwanted immunogenicity effects. Immune responses to therapeutic protein products can limit product efficacy as well as affect patient safety.

Scientist Live - Biotechnology, 30th May 2014

By: Samuel Altun, Lena Heffler and Teodor Aastrup

It is of great importance to understand and verify desired and unwanted immunogenicity effects. Immune responses to therapeutic protein products can limit product efficacy as well as affect patient safety.

Consequently, immunogenicity-related factors should be considered early in the product development process. Guidance for immunogenicity testing is provided by the U.S. Food and Drug Administration (FDA). Factors such as aggregation, off-target interactions, target clustering and neutralising antibodies are mentioned as examples that should be evaluated.

The discussion here pertains to a proprietary quartz crystal microbalance (QCM) based biosensor that offers label-free applications to study the abovementioned factors in real time.

Read the full article (link opens in new window).

Read more about how Attana instruments can be used within immunogenicity here.